LENSAR (LNSR) Expected to Announce Earnings on Thursday

Key Points

• LENSAR is expected to report Q1 2026 results before the market opens on May 7, 2026, with consensus estimates of $0.185 EPS and $13.4M revenue and an earnings call scheduled for 7:00 AM ET.
• The company missed the prior quarter—reporting a ($0.12) EPS vs. ($0.10) expected and $16.03M revenue vs. $20.30M expected—and its shares trade with a 1‑year range of $5.06–$14.31 and a market cap of about $65.2M.
• Institutional activity has increased (notable positions by Goldman, Acadian, Geode, JPMorgan) with roughly 40.15% institutional ownership, while analysts hold a consensus "Hold" rating and an average price target of $10.00 (two Buys, one Sell).

LENSAR (NASDAQ:LNSR - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect LENSAR to post earnings of $0.1850 per share and revenue of $13.40 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 7:00 AM ET.

LENSAR (NASDAQ:LNSR - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The business had revenue of $16.03 million during the quarter, compared to the consensus estimate of $20.30 million.

LENSAR Price Performance

Shares of LENSAR stock opened at $5.39 on Thursday. LENSAR has a 1 year low of $5.06 and a 1 year high of $14.31. The business has a 50-day moving average of $7.90 and a two-hundred day moving average of $10.30. The company has a market capitalization of $65.20 million, a P/E ratio of -1.86 and a beta of 0.99.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LNSR. Goldman Sachs Group Inc. bought a new position in shares of LENSAR during the first quarter worth about $546,000. Acadian Asset Management LLC bought a new position in shares of LENSAR during the first quarter worth about $257,000. Geode Capital Management LLC grew its holdings in shares of LENSAR by 103.9% during the second quarter. Geode Capital Management LLC now owns 219,373 shares of the company's stock worth $2,890,000 after buying an additional 111,802 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of LENSAR by 584.3% during the second quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company's stock worth $62,000 after buying an additional 3,991 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new position in LENSAR during the second quarter valued at approximately $105,000. 40.15% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on LNSR shares. Lake Street Capital upgraded LENSAR from a "hold" rating to a "buy" rating and set a $10.00 price target for the company in a report on Wednesday, April 1st. BTIG Research upgraded LENSAR from a "neutral" rating to a "buy" rating and set a $10.00 price target for the company in a report on Tuesday, March 17th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of LENSAR in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $10.00.

About LENSAR

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.